newsfilter
← Latest News
Business Wire·

LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology